<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:29PM UTC 2026-05-15--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:agpu="http://www.precisiontherapeutics.com/20260331" xmlns:country="http://xbrl.sec.gov/country/2026" xmlns:currency="http://xbrl.sec.gov/currency/2026" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2026" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2026" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2026" xmlns:sic="http://xbrl.sec.gov/sic/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:srt-types="http://fasb.org/srt-types/2026" xmlns:stpr="http://xbrl.sec.gov/stpr/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:us-types="http://fasb.org/us-types/2026" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.precisiontherapeutics.com/20260331">
  <xsd:import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2026" schemaLocation="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2026" schemaLocation="https://xbrl.sec.gov/exch/2026/exch-2026.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2026" schemaLocation="https://xbrl.sec.gov/currency/2026/currency-2026.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2026" schemaLocation="https://xbrl.sec.gov/country/2026/country-2026.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2026" schemaLocation="https://xbrl.sec.gov/naics/2026/naics-2026.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2026" schemaLocation="https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2026" schemaLocation="https://xbrl.sec.gov/sic/2026/sic-2026.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agpu-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agpu-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agpu-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agpu-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-net-loss-unaudited" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-condensed-consolidated-statements-of-net-loss-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Condensed Consolidated Statements of Net Loss (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statement-of-stockholders-equity-deficit-unaudited" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-condensed-consolidated-statement-of-stockholders-equity-deficit-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flows-unaudited" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-company-information" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-1-company-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Company Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-discontinued-operations" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-3-discontinued-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Discontinued Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-contracts-with-customers" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-4-contracts-with-customers">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Contracts With Customers</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-digital-assets" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-5-digital-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Digital Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-fair-value-measurements" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-6-fair-value-measurements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-property-and-equipment-net" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-7-property-and-equipment-net">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Property and Equipment, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-contingencies" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-8-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-leases" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-9-leases">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-note-payable" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-10-note-payable">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - Note Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockholders-equity" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-11-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-stockbased-compensation-" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-12-stockbased-compensation-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 12 - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-net-loss-per-share-" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-13-net-loss-per-share-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 13 - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-segment-information" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-14-segment-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 14 - Segment Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-subsequent-events" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-15-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 15 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995445 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-discontinued-operations-tables" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-3-discontinued-operations-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995446 - Disclosure - Note 3 - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-digital-assets-tables" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-5-digital-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995447 - Disclosure - Note 5 - Digital Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-fair-value-measurements-tables" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-6-fair-value-measurements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995448 - Disclosure - Note 6 - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-property-and-equipment-net-tables" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-7-property-and-equipment-net-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995449 - Disclosure - Note 7 - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-leases-tables" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-9-leases-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995450 - Disclosure - Note 9 - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockholders-equity-tables" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-11-stockholders-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995451 - Disclosure - Note 11 - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-stockbased-compensation-tables" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-12-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995452 - Disclosure - Note 12 - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-net-loss-per-share-tables" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-13-net-loss-per-share-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995453 - Disclosure - Note 13 - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-segment-information-tables" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-14-segment-information-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995454 - Disclosure - Note 14 - Segment Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-company-information-details-textual" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-1-company-information-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995455 - Disclosure - Note 1 - Company Information (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-discontinued-operations-details-textual" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-3-discontinued-operations-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995456 - Disclosure - Note 3 - Discontinued Operations (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-discontinued-operations-schedule-of-disposal-groups-by-balance-sheet-classification-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-3-discontinued-operations-schedule-of-disposal-groups-by-balance-sheet-classification-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995457 - Disclosure - Note 3 - Discontinued Operations - Schedule of Disposal Groups by Balance Sheet Classification (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-discontinued-operations-schedule-of-disposal-groups-including-discontinued-operations-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-3-discontinued-operations-schedule-of-disposal-groups-including-discontinued-operations-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995458 - Disclosure - Note 3 - Discontinued Operations - Schedule of Disposal Groups Including Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-contracts-with-customers-details-textual" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-4-contracts-with-customers-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995459 - Disclosure - Note 4 - Contracts With Customers (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-digital-assets-details-textual" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-5-digital-assets-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995460 - Disclosure - Note 5 - Digital Assets (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-crypto-asset-holdings-crypto-asset-holding-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-5-crypto-asset-holdings-crypto-asset-holding-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995461 - Disclosure - Note 5 - Crypto Asset Holdings - Crypto Asset, Holding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-digital-assets-reconciliation-of-digital-assets-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-5-digital-assets-reconciliation-of-digital-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995462 - Disclosure - Note 5 - Digital Assets - Reconciliation of Digital Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-fair-value-measurements-details-textual" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-6-fair-value-measurements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995463 - Disclosure - Note 6 - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-fair-value-measurements-fair-value-of-assets-and-liabilities-on-a-recurring-basis-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-6-fair-value-measurements-fair-value-of-assets-and-liabilities-on-a-recurring-basis-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995464 - Disclosure - Note 6 - Fair Value Measurements - Fair Value of Assets and Liabilities on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-property-and-equipment-net-details-textual" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-7-property-and-equipment-net-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995465 - Disclosure - Note 7 - Property and Equipment, Net (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-property-and-equipment-net-schedule-of-property-plant-and-equipment-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-7-property-and-equipment-net-schedule-of-property-plant-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995466 - Disclosure - Note 7 - Property and Equipment, Net - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-leases-details-textual" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-9-leases-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995467 - Disclosure - Note 9 - Leases (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-leases-lease-information-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-9-leases-lease-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995468 - Disclosure - Note 9 - Leases - Lease Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-leases-rent-obligation-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-9-leases-rent-obligation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995469 - Disclosure - Note 9 - Leases - Rent Obligation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-note-payable-details-textual" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-10-note-payable-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995470 - Disclosure - Note 10 - Note Payable (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockholders-equity-details-textual" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-11-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995471 - Disclosure - Note 11 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockholders-equity-schedule-of-warrants-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-11-stockholders-equity-schedule-of-warrants-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995472 - Disclosure - Note 11 - Stockholders' Equity - Schedule of Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockholders-equity-warrant-valuation-assumption-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-11-stockholders-equity-warrant-valuation-assumption-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995473 - Disclosure - Note 11 - Stockholders' Equity - Warrant Valuation Assumption (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-stockbased-compensation-details-textual" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-12-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995474 - Disclosure - Note 12 - Stock-Based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-stockbased-compensation-schedule-of-nonvested-restricted-stock-units-activity-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-12-stockbased-compensation-schedule-of-nonvested-restricted-stock-units-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995475 - Disclosure - Note 12 - Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-stockbased-compensation-schedule-of-sharebased-compensation-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-12-stockbased-compensation-schedule-of-sharebased-compensation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995476 - Disclosure - Note 12 - Stock-Based Compensation - Schedule of Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-net-loss-per-share-details-textual" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-13-net-loss-per-share-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995477 - Disclosure - Note 13 - Net Loss Per Share (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-net-loss-per-share-schedule-of-earnings-per-share-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-13-net-loss-per-share-schedule-of-earnings-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995478 - Disclosure - Note 13 - Net Loss Per Share - Schedule of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-net-loss-per-share-schedule-of-antidilutive-securities-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-13-net-loss-per-share-schedule-of-antidilutive-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995479 - Disclosure - Note 13 - Net Loss Per Share - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-segment-information-details-textual" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-14-segment-information-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995480 - Disclosure - Note 14 - Segment Information (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-segment-information-segments-details" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-14-segment-information-segments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995481 - Disclosure - Note 14 - Segment Information - Segments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-subsequent-events-details-textual" roleURI="http://www.precisiontherapeutics.com/20260331/role/statement-note-15-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995482 - Disclosure - Note 15 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="agpu_AethirATHMember" name="AethirATHMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_AggregateNotionalValue" name="AggregateNotionalValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="agpu_AnnualBaseSalary" name="AnnualBaseSalary" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="agpu_AnnualCashBonusPercentageOfBaseSalary" name="AnnualCashBonusPercentageOfBaseSalary" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_AprilAgreementEnterpriseInfrastructureContractMember" name="AprilAgreementEnterpriseInfrastructureContractMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_AssetBasedManagementFeePercent" name="AssetBasedManagementFeePercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_AssetManagementAgreementTerm" name="AssetManagementAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_AssetsExcludingDiscontinuedOperations" name="AssetsExcludingDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="agpu_BirminghamLaboratoryAndEaganBusinessMember" name="BirminghamLaboratoryAndEaganBusinessMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_BonusTokensPercent" name="BonusTokensPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="agpu_CashPIPESPAMember" name="CashPIPESPAMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_CashPIPEWarrantsMember" name="CashPIPEWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentOfStockPrice" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentOfStockPrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" name="ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_ClassOfWarrantOrRightExpiredDuringPeriod" name="ClassOfWarrantOrRightExpiredDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" name="ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_ClassOfWarrantOrRightGrantDateFairValue" name="ClassOfWarrantOrRightGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="agpu_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" name="ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_ComputeServicesAndTreasuryManagementSegmentMember" name="ComputeServicesAndTreasuryManagementSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_ComputeServicesMember" name="ComputeServicesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_ContractObligationContractValue" name="ContractObligationContractValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="agpu_ContractObligationTermOfContract" name="ContractObligationTermOfContract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_CostOfBookingComputeUsingCryptoAssets" name="CostOfBookingComputeUsingCryptoAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="agpu_CryptoAssetHostReceivable" name="CryptoAssetHostReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="agpu_CryptoAssetReceivable" name="CryptoAssetReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="agpu_CryptoAssetReceivableCurrent" name="CryptoAssetReceivableCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="agpu_CryptoPIPEWarrantsMember" name="CryptoPIPEWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_CustomerOneMember" name="CustomerOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_DebtInstrumentNumberOfMonthlyInstallment" name="DebtInstrumentNumberOfMonthlyInstallment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_DiscontinuedOperationIncomeLossFromDisposalOfDiscontinuedOperationOther" name="DiscontinuedOperationIncomeLossFromDisposalOfDiscontinuedOperationOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="agpu_DiscountedValue" name="DiscountedValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="agpu_DisposalGroupIncludingDiscontinuedOperationLeaseCurrentLiabilities" name="DisposalGroupIncludingDiscontinuedOperationLeaseCurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="agpu_DisposalGroupIncludingDiscontinuedOperationOperationsExpense" name="DisposalGroupIncludingDiscontinuedOperationOperationsExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="agpu_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense" name="DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_DrugDiscoveryServicesMember" name="DrugDiscoveryServicesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_DrugDiscoveryServicesSegmentMember" name="DrugDiscoveryServicesSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_EaganBusinessMember" name="EaganBusinessMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_February182025OfferingMember" name="February182025OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_IncentiveFeePercent" name="IncentiveFeePercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_InsurancePolicyFinancingMember" name="InsurancePolicyFinancingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_ManagedAssetsProfitsIncentiveTriggerPercentage" name="ManagedAssetsProfitsIncentiveTriggerPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_NetIncomeLossExcludingDiscontinuedOperations" name="NetIncomeLossExcludingDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_NumberOfCustomers" name="NumberOfCustomers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_NumberOfTumorSamples" name="NumberOfTumorSamples" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_OperatingLeaseRightOfUseAssetAccumulatedAmortization" name="OperatingLeaseRightOfUseAssetAccumulatedAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="agpu_OperatingLeaseRightOfUseAssetGross" name="OperatingLeaseRightOfUseAssetGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="agpu_PercentOfOutstandingCommonStock" name="PercentOfOutstandingCommonStock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="agpu_PlacementAgentWarrantsMember" name="PlacementAgentWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_PolicyTable" name="PolicyTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_PrefundedWarrantMember" name="PrefundedWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_RealizedGainOnPrepaymentsUsingDigitalAssets" name="RealizedGainOnPrepaymentsUsingDigitalAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_RegisteredDirectOfferingPlacementAgentWarrantsMember" name="RegisteredDirectOfferingPlacementAgentWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_RenovaroAcquisitionMember" name="RenovaroAcquisitionMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_RenovaroExtensionAgreementMember" name="RenovaroExtensionAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_ReverseStockSplitMember" name="ReverseStockSplitMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_RiskAndUncertaintiesPolicyTextBlock" name="RiskAndUncertaintiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_SaleOfStockAdditionalAmount" name="SaleOfStockAdditionalAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="agpu_SaleOfStockAgentPlacementFeePercentOfGrossProceeds" name="SaleOfStockAgentPlacementFeePercentOfGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_SaleOfStockBeneficialOwnershipVotingPower" name="SaleOfStockBeneficialOwnershipVotingPower" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_SaleOfStockCommissionsPercent" name="SaleOfStockCommissionsPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_SaleOfStockDiscountRate" name="SaleOfStockDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_SaleOfStockManagementFeePercentOfGrossProceeds" name="SaleOfStockManagementFeePercentOfGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_SaleOfStockMaximumAmount" name="SaleOfStockMaximumAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_SaleOfStockMaximumShares" name="SaleOfStockMaximumShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_SaleOfStockPlacementAgentWarrantsAssignedNumberOfSecuritiesCalledByWarrantsPercentOfSharesSold" name="SaleOfStockPlacementAgentWarrantsAssignedNumberOfSecuritiesCalledByWarrantsPercentOfSharesSold" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="agpu_SaleOfStockRemainingAvailableBalance" name="SaleOfStockRemainingAvailableBalance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="agpu_SalesAgreementMember" name="SalesAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_ScheduleOfDisposalGroupByBalanceSheetClassificationTableTextBlock" name="ScheduleOfDisposalGroupByBalanceSheetClassificationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_SideLetterAgreementMember" name="SideLetterAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_StandbyEquityPurchaseAgreementMember" name="StandbyEquityPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="agpu_StockIssuedForVestingOfRestrictedStockUnits" name="StockIssuedForVestingOfRestrictedStockUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_StockWarrantsMember" name="StockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_StrategicAdvisorWarrantsMember" name="StrategicAdvisorWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_VestingEquallyOverTheFollowing24MonthsMember" name="VestingEquallyOverTheFollowing24MonthsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_VestingOnTheFirstAnniversaryOfApril12026Member" name="VestingOnTheFirstAnniversaryOfApril12026Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_VestingOnTheFirstAnniversaryOfApril162026Member" name="VestingOnTheFirstAnniversaryOfApril162026Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="agpu_WarrantsOrRightsCommissions" name="WarrantsOrRightsCommissions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="agpu_WarrantsOrRightsCommissionsPercent" name="WarrantsOrRightsCommissionsPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-11-stockholders-equity-schedule-of-warrants-details" name="statement-statement-note-11-stockholders-equity-schedule-of-warrants-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-11-stockholders-equity-tables" name="statement-statement-note-11-stockholders-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-11-stockholders-equity-warrant-valuation-assumption-details" name="statement-statement-note-11-stockholders-equity-warrant-valuation-assumption-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-12-stockbased-compensation-schedule-of-nonvested-restricted-stock-units-activity-details" name="statement-statement-note-12-stockbased-compensation-schedule-of-nonvested-restricted-stock-units-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-12-stockbased-compensation-schedule-of-sharebased-compensation-details" name="statement-statement-note-12-stockbased-compensation-schedule-of-sharebased-compensation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-12-stockbased-compensation-tables" name="statement-statement-note-12-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-13-net-loss-per-share-schedule-of-antidilutive-securities-details" name="statement-statement-note-13-net-loss-per-share-schedule-of-antidilutive-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-13-net-loss-per-share-schedule-of-earnings-per-share-details" name="statement-statement-note-13-net-loss-per-share-schedule-of-earnings-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-13-net-loss-per-share-tables" name="statement-statement-note-13-net-loss-per-share-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-14-segment-information-segments-details" name="statement-statement-note-14-segment-information-segments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-14-segment-information-segments-details350802DD-F542-4372-B203-D4DF6DF563F9" name="statement-statement-note-14-segment-information-segments-details350802DD-F542-4372-B203-D4DF6DF563F9" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-14-segment-information-tables" name="statement-statement-note-14-segment-information-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-3-discontinued-operations-schedule-of-disposal-groups-by-balance-sheet-classification-details" name="statement-statement-note-3-discontinued-operations-schedule-of-disposal-groups-by-balance-sheet-classification-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-3-discontinued-operations-schedule-of-disposal-groups-including-discontinued-operations-details" name="statement-statement-note-3-discontinued-operations-schedule-of-disposal-groups-including-discontinued-operations-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-3-discontinued-operations-tables" name="statement-statement-note-3-discontinued-operations-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-5-crypto-asset-holdings-crypto-asset-holding-details" name="statement-statement-note-5-crypto-asset-holdings-crypto-asset-holding-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-5-digital-assets-reconciliation-of-digital-assets-details" name="statement-statement-note-5-digital-assets-reconciliation-of-digital-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-5-digital-assets-tables" name="statement-statement-note-5-digital-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-6-fair-value-measurements-fair-value-of-assets-and-liabilities-on-a-recurring-basis-details" name="statement-statement-note-6-fair-value-measurements-fair-value-of-assets-and-liabilities-on-a-recurring-basis-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-6-fair-value-measurements-fair-value-of-assets-and-liabilities-on-a-recurring-basis-details28432E9A-D9A4-4586-80BA-002094EAB030" name="statement-statement-note-6-fair-value-measurements-fair-value-of-assets-and-liabilities-on-a-recurring-basis-details28432E9A-D9A4-4586-80BA-002094EAB030" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-6-fair-value-measurements-tables" name="statement-statement-note-6-fair-value-measurements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-7-property-and-equipment-net-schedule-of-property-plant-and-equipment-details" name="statement-statement-note-7-property-and-equipment-net-schedule-of-property-plant-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-7-property-and-equipment-net-tables" name="statement-statement-note-7-property-and-equipment-net-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-9-leases-lease-information-details" name="statement-statement-note-9-leases-lease-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-9-leases-rent-obligation-details" name="statement-statement-note-9-leases-rent-obligation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-note-9-leases-tables" name="statement-statement-note-9-leases-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="agpu_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
